Dr Stacey Anne Gould

Interests

I am currently exploring ways to target programmed axon death for therapeutic effect. I study the role of SARM1 activation after a range of physical and neurotoxic triggers, and how subsequent axon degeneration can be prevented using compounds with therapeutic potential. My earlier work in behavioural neuropharmacology focussed on peripheral mechanisms of pain generation and ways to improve preclinical predictability of analgesic efficacy in spontaneous pain assays.

Research Focus

Keywords

Wallerian degeneration

Programmed axon death

Pain

Therapeutics

Behaviour

Clinical conditions

Alzheimer's disease

Dementia

Diabetes

No direct clinical relevance

Pain

Peripheral neuropathy

Equipment

Behavioural analysis

Cell culture

Enzyme assays

Fluorescence microscopy

Immunohistochemistry

Microscopy

Neuropsychological testing

Collaborators

No collaborators listed

Associated News Items


    Publications

    in press

    Gould SA, White M, Wilbrey AL, Pór E, Coleman MP, Adalbert R (in press), “Protection against oxaliplatin-induced mechanical and thermal hypersensitivity in Sarm1-/- mice.” Exp Neurol. 338:113607

    2018

    Adalbert R, Milde S, Durrant C, Ando K, Stygelbout V, Yilmaz Z, Gould S, Brion JP, Coleman MP (2018), “ Interaction between a MAPT variant causing frontotemporal dementia and mutant APP affects axonal transport.” Neurobiol Aging 68:68-75

    Rutten K, Gould SA, Bryden L, Doods H, Christoph T, Pekcec A (2018), “ Standard analgesics reverse burrowing deficits in a rat CCI model of neuropathic pain, but not in models of type 1 and type 2 diabetes-induced neuropathic pain” Behav Brain Res 350:129-138

    2015

    Gould SA, Doods H, Lamla T, Pekcec A (2015), “Pharmacological characterization of intraplantar Complete Freund's Adjuvant-induced burrowing deficits ” Behav Brain Res 301:142-51